Abbott Laboratories reported fourth-quarter 2025 sales of US$11,459 million, with net income dropping to US$1,776 million and diluted EPS from continuing operations at US$1.01, compared with the prior year.
The earnings shortfall in Nutrition and Diagnostics coincided with CEO Robert Ford purchasing over US$2 million of Abbott shares, highlighting leadership’s conviction in the company’s long-term direction despite current pressure points.
With the share price weaker over the past week,…
The earnings shortfall in Nutrition and Diagnostics coincided with CEO Robert Ford purchasing over US$2 million of Abbott shares, highlighting leadership’s conviction in the company’s long-term direction despite current pressure points.
With the share price weaker over the past week,…
